Vertex Pharmaceuticals (NASDAQ:VRTX) PT Set at $530.00 by BMO Capital Markets

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) has been given a $530.00 target price by analysts at BMO Capital Markets in a research note issued on Tuesday, Marketbeat reports. The firm currently has an “outperform” rating on the pharmaceutical company’s stock. BMO Capital Markets’ price objective would suggest a potential upside of 37.43% from the […]

Leave a Reply

Your email address will not be published.

Previous post Under Armour (UAA) Expected to Announce Quarterly Earnings on Friday
Next post Replimune Group (REPL) Projected to Post Quarterly Earnings on Thursday